S&P 500   3,117.43 (+0.15%)
DOW   27,677.79 (+0.10%)
QQQ   202.43 (+0.51%)
AAPL   265.58 (+1.47%)
FB   199.36 (+0.33%)
MSFT   149.93 (+0.05%)
GOOGL   1,326.96 (+0.61%)
AMZN   1,740.48 (-1.15%)
CGC   18.60 (+1.20%)
NVDA   208.74 (-0.32%)
MU   46.62 (+0.69%)
BABA   200.00 (+3.23%)
GE   10.79 (-1.01%)
TSLA   330.37 (-0.80%)
T   38.19 (+0.24%)
AMD   39.62 (-0.18%)
ACB   2.44 (-1.61%)
F   8.93 (-0.22%)
PRI   134.30 (+0.83%)
NFLX   302.86 (-0.48%)
BAC   33.09 (-0.18%)
GILD   65.93 (-1.23%)
DIS   147.44 (-0.57%)
S&P 500   3,117.43 (+0.15%)
DOW   27,677.79 (+0.10%)
QQQ   202.43 (+0.51%)
AAPL   265.58 (+1.47%)
FB   199.36 (+0.33%)
MSFT   149.93 (+0.05%)
GOOGL   1,326.96 (+0.61%)
AMZN   1,740.48 (-1.15%)
CGC   18.60 (+1.20%)
NVDA   208.74 (-0.32%)
MU   46.62 (+0.69%)
BABA   200.00 (+3.23%)
GE   10.79 (-1.01%)
TSLA   330.37 (-0.80%)
T   38.19 (+0.24%)
AMD   39.62 (-0.18%)
ACB   2.44 (-1.61%)
F   8.93 (-0.22%)
PRI   134.30 (+0.83%)
NFLX   302.86 (-0.48%)
BAC   33.09 (-0.18%)
GILD   65.93 (-1.23%)
DIS   147.44 (-0.57%)
S&P 500   3,117.43 (+0.15%)
DOW   27,677.79 (+0.10%)
QQQ   202.43 (+0.51%)
AAPL   265.58 (+1.47%)
FB   199.36 (+0.33%)
MSFT   149.93 (+0.05%)
GOOGL   1,326.96 (+0.61%)
AMZN   1,740.48 (-1.15%)
CGC   18.60 (+1.20%)
NVDA   208.74 (-0.32%)
MU   46.62 (+0.69%)
BABA   200.00 (+3.23%)
GE   10.79 (-1.01%)
TSLA   330.37 (-0.80%)
T   38.19 (+0.24%)
AMD   39.62 (-0.18%)
ACB   2.44 (-1.61%)
F   8.93 (-0.22%)
PRI   134.30 (+0.83%)
NFLX   302.86 (-0.48%)
BAC   33.09 (-0.18%)
GILD   65.93 (-1.23%)
DIS   147.44 (-0.57%)
S&P 500   3,117.43 (+0.15%)
DOW   27,677.79 (+0.10%)
QQQ   202.43 (+0.51%)
AAPL   265.58 (+1.47%)
FB   199.36 (+0.33%)
MSFT   149.93 (+0.05%)
GOOGL   1,326.96 (+0.61%)
AMZN   1,740.48 (-1.15%)
CGC   18.60 (+1.20%)
NVDA   208.74 (-0.32%)
MU   46.62 (+0.69%)
BABA   200.00 (+3.23%)
GE   10.79 (-1.01%)
TSLA   330.37 (-0.80%)
T   38.19 (+0.24%)
AMD   39.62 (-0.18%)
ACB   2.44 (-1.61%)
F   8.93 (-0.22%)
PRI   134.30 (+0.83%)
NFLX   302.86 (-0.48%)
BAC   33.09 (-0.18%)
GILD   65.93 (-1.23%)
DIS   147.44 (-0.57%)
Log in

NASDAQ:CYCCP - Cyclacel Pharmaceuticals Inc 6% Conv. Pref. Shrs Stock Price, Forecast & News

$4.25
-0.26 (-5.76 %)
(As of 12/5/2019 04:00 PM ET)
Today's Range
$4.25
Now: $4.25
$4.60
50-Day Range
$3.90
MA: $4.77
$5.13
52-Week Range
$3.87
Now: $4.25
$7.00
Volume1,393 shs
Average Volume929 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend Yield0.12%
BetaN/A
Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include sapacitabine, a novel orally-available nucleoside analog that is in Phase III clinical trial for the front-line treatment of acute myeloid leukemia; and Phase II clinical trial for the treatment of myelodysplastic syndromes. Its oncology development programs also comprise Seliciclib, a first-generation cyclin dependent kinase (CDK) inhibitor that is in phase I/II combination study with sapacitabine for BRCA mutations; and CYC065, a second generation CDK inhibitor, which is in Phase I clinical trial for solid tumors. In addition, the company's oncology development programs include CYC140, a polo-like kinase inhibitor program that is in preclinical development stage. Cyclacel Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CYCCP
CUSIPN/A
Phone+1-908-5177330

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees14
Next Earnings DateN/A
OptionableNot Optionable

Receive CYCCP News and Ratings via Email

Sign-up to receive the latest news and ratings for CYCCP and its competitors with MarketBeat's FREE daily newsletter.


Cyclacel Pharmaceuticals Inc 6% Conv. Pref. Shrs (NASDAQ:CYCCP) Frequently Asked Questions

What is Cyclacel Pharmaceuticals Inc 6% Conv. Pref. Shrs' stock symbol?

Cyclacel Pharmaceuticals Inc 6% Conv. Pref. Shrs trades on the NASDAQ under the ticker symbol "CYCCP."

How often does Cyclacel Pharmaceuticals Inc 6% Conv. Pref. Shrs pay dividends? What is the dividend yield for Cyclacel Pharmaceuticals Inc 6% Conv. Pref. Shrs?

Cyclacel Pharmaceuticals Inc 6% Conv. Pref. Shrs announced a -- dividend on Thursday, September 12th. Stockholders of record on Monday, October 14th will be paid a dividend of $0.15 per share on Friday, November 1st. This represents a dividend yield of 12.3%. The ex-dividend date of this dividend is Thursday, October 10th. View Cyclacel Pharmaceuticals Inc 6% Conv. Pref. Shrs' Dividend History.

Has Cyclacel Pharmaceuticals Inc 6% Conv. Pref. Shrs been receiving favorable news coverage?

Media stories about CYCCP stock have trended somewhat positive recently, according to InfoTrie Sentiment. InfoTrie scores the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Cyclacel Pharmaceuticals Inc 6% Conv. Pref. Shrs earned a coverage optimism score of 1.3 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Cyclacel Pharmaceuticals Inc 6% Conv. Pref. Shrs.

Who are some of Cyclacel Pharmaceuticals Inc 6% Conv. Pref. Shrs' key competitors?

What other stocks do shareholders of Cyclacel Pharmaceuticals Inc 6% Conv. Pref. Shrs own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cyclacel Pharmaceuticals Inc 6% Conv. Pref. Shrs investors own include Cytokinetics (CYTK), Riot Blockchain (RIOT), XOMA (XOMA), Tesla (TSLA), Great Basin Scientific (GBSN), Smart Global (SGH), Ambarella (AMBA), Arena Pharmaceuticals (ARNA), OHR Pharmaceutical (OHRP) and OncoSec Medical (ONCS).

Who are Cyclacel Pharmaceuticals Inc 6% Conv. Pref. Shrs' key executives?

Cyclacel Pharmaceuticals Inc 6% Conv. Pref. Shrs' management team includes the folowing people:
  • Mr. Spiro George Rombotis, Pres, CEO & Exec. Director (Age 60)
  • Mr. Paul McBarron, Exec. VP of Fin., CFO, COO, Sec. & Exec. Director (Age 58)
  • Dr. Judy H. Chiao, VP of Clinical Devel. & Regulatory Affairs (Age 59)
  • Ms. Gill Christie, Director of HR (Age 62)
  • Dr. Robert Westwood Ph.D., Head of Preclinical Devel. and VP of Chemistry & Preclinical Devel. (Age 75)

How do I buy shares of Cyclacel Pharmaceuticals Inc 6% Conv. Pref. Shrs?

Shares of CYCCP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Cyclacel Pharmaceuticals Inc 6% Conv. Pref. Shrs' stock price today?

One share of CYCCP stock can currently be purchased for approximately $4.25.

What is Cyclacel Pharmaceuticals Inc 6% Conv. Pref. Shrs' official website?

The official website for Cyclacel Pharmaceuticals Inc 6% Conv. Pref. Shrs is http://www.cyclacel.com/.

How can I contact Cyclacel Pharmaceuticals Inc 6% Conv. Pref. Shrs?

Cyclacel Pharmaceuticals Inc 6% Conv. Pref. Shrs' mailing address is 200 Connell Dr Ste 1500, BERKELEY HEIGHTS, NJ 07922-2811, United States. The company can be reached via phone at +1-908-5177330.


MarketBeat Community Rating for Cyclacel Pharmaceuticals Inc 6% Conv. Pref. Shrs (NASDAQ CYCCP)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  81 (Vote Outperform)
Underperform Votes:  86 (Vote Underperform)
Total Votes:  167
MarketBeat's community ratings are surveys of what our community members think about Cyclacel Pharmaceuticals Inc 6% Conv. Pref. Shrs and other stocks. Vote "Outperform" if you believe CYCCP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CYCCP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/5/2019 by MarketBeat.com Staff

Featured Article: Neutral Rating

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel